Furthermore, JAM-A expression declined in renal cancer (Gutwein et al., 2009), gastric cancer (Huang et al., 2014), and multiple myeloma (MM) (Solimando et al., 2018) and impaired these cancer cells migration and invasion. Here, F11R is linked to cancer.